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ABSTRACT
Coronaviruses (CoVs) are enveloped, positive sense, single-stranded RNA viruses. The viruses have adapted to infect a
large number of animal species, ranging from bats to camels. At present, seven CoVs infect humans, of which Severe
Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is responsible for causing the Coronavirus Disease 2019
(COVID-19) in humans. Since its emergence in late 2019, SARS-CoV-2 has spread rapidly across the globe. Healthcare
systems around the globe have been stretched beyond their limits posing new challenges to emergency healthcare
services and critical care. The outbreak continues to jeopardize human health, social life and economy. All known
human CoVs have zoonotic origins. Recent detection of SARS-CoV-2 in pet, zoo and certain farm animals has
highlighted its potential for reverse zoonosis. This scenario is particularly alarming, since these animals could be
potential reservoirs for secondary zoonotic infections. In this article, we highlight interspecies SARS-CoV-2 infections
and focus on the reverse zoonotic potential of this virus. We also emphasize the importance of potential secondary
zoonotic events and the One-Health and One-World approach to tackle such future pandemics.
ARTICLE HISTORY Received 14 June 2020; Revised 25 August 2020; Accepted 20 September 2020
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Introduction
The novel coronavirus (2019-nCoV) was first detected
in humans suffering from an atypical fatal pneumonia
in early December 2019 in Wuhan, China. Although
initial zoonotic transmission was suggested via the
Huanan seafood market that also traded live wild ani-
mals [1, 2], the role of this market in spreading this
virus remained unclear. Isolation of the virus from
environmental samples collected from this market
suggested the possibility of its crossing the species
barrier from animal(s) to humans. On 7 January
2020, the 2019-nCoV was isolated from the nasal
swab of a human patient [3], and re-named as
SARS-CoV-2 by the Coronaviridae Study Group
(CSG) of the International Committee on Taxonomy
of Viruses (ICTV; [4]). The World Health Organiz-
ation (WHO) named the resulting disease as
COVID-19, an acronym derived from the
Coronavirus Disease of 2019. On 30 January 2020,
the WHO declared the coronavirus outbreak as a Pub-
lic Health Emergency of International Concern. With
its rapid spread across continents, the WHO categor-
ized the COVID-19 as a “Pandemic” on 11 March
2020. As of 24 August 2020, COVID-19 had caused
over 816,535 deaths with more than 23,800,750
reported infections worldwide with a global case fatal-
ity rate (CFR) of 3.43% (covidvisualizer.com). Many
countries including the USA and Canada have
declared the COVID-19 epidemic as a “National
Emergency” and have mobilized extra financial and
public health resources to combat it.
Animal coronaviruses
Coronaviruses (CoVs) are subdivided into four gen-
era: α, β, γ and δ. Since late 1930s, different animal
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CoVs have been isolated from various infected ani-
mals and avian species including rodents, cattle,
pigs, cats, camels, bats, dogs and and chickens
and turkeys [5–7]. The viruses cause respiratory,
reproductive, gastrointestinal, hepatic, neurological
and/or other systemic pathologies in a wide range
of animal and avian species (Figure 1; [5–7]). Phy-
logenetic analyses of two porcine CoV, Porcine Res-
piratory Virus (PRCV) and Transmissible
Gastroenteritis Virus (TGEV) revealed that the for-
mer originated from the latter through a deletion in
a part of the Spike (S) protein that altered the tis-
sue tropism of the virus from the gastrointestinal
tract to the respiratory tract [5–10]. The deletion
also resulted in reduced virulence of the new var-
iant. It is noteworthy that all animal (and human)
coronaviruses belong to the α and β genera with
the exception of one, the Porcine Delta CoV
(PDCoV; Figure 1). The PRCV, porcine enteric
diarrhea virus (PEDV) and the more recently
emerged swine acute diarrhea syndrome corona-
virus (SADS-CoV) [7] cause significant economic
losses to swine industry. The CoVs belonging to
the γ genus mainly infect domestic birds. The
avian infectious bronchitis virus (IBV), the first
CoV detected in 1937 in chickens [7–9], affects
the respiratory, renal and reproductive systems of
chickens. Delta CoVs mainly infect wild birds,
including bulbul coronavirus and sparrow corona-
virus [6, 7, 10].
Zoonotic origins of human coronaviruses
At present, seven species of CoVs are known to infect
humans (Figure 2). Four of these human CoVs
(HCoVs) namely 229E, OC43, NL63 and HKU1 are
endemic, and cause 15-30% cases of common cold
in humans, mostly during winter and early spring [5,
8–13]. The 229E strain B814 was the first HCoV ident-
ified in 1966 in the nasal swab of a human patient, who
had contracted “common cold” [5, 8–15]. HCoV-
OC43 was isolated in 1967 from the organ culture
from an infected human [5, 8, 9, 13–15]. Comparative
phylogenetic analyses of human and animal CoVs
Figure 1. Selected important coronaviruses causing diseases in animal species. The figure shows different coronaviruses, their
genera, main clinical symptoms, host species, and tissue/organ tropism. PEDV: Porcine Epidemic Diarrhea Virus; TGEV: Transmis-
sible Gastroenteritis Virus; PRCV: Porcine Respiratory Coronavirus; FIPV: Feline Infectious Peritonitis Virus; FECoV: Feline Enteric
Coronavirus; CCoV: Canine Coronavirus; PDCoV: Porcine Delta Coronavirus; TCoV: Turkey Coronavirus; IBV: Infectious Bronchitis
Virus; PHEV: Porcine Hemagglutinating & Encephalomyelitis Virus; Equine CoV: Equine Coronavirus; BCoV: Bovine Coronavirus;
Severe Acute Diarrhea Syndrome Coronavirus: SADS-CoV.
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suggest that 229E and OC43 jumped their animal
reservoirs (bats and cattle, respectively) to infect
humans within the last 200 years ([8, 9, 11–15];
Figure 2). HKU1, isolated in 2004 from an elderly
patient in Hong Kong, is believed to have originated
from mice [5, 8, 9, 14, 15], while NL63, isolated in
the same year from a seven-month old child in the
Netherlands, jumped from bats to an unidentified
intermediate host before crossing species barrier to
humans ([5, 13, 14]; Figure 2). Within the last two dec-
ades, three β-CoVs have jumped from animal reser-
voirs directly or through intermediate hosts to cause
severe diseases in humans; these are Severe Acute Res-
piratory Syndrome coronavirus (SARS-CoV-1) [14–
21], Middle East Respiratory Syndrome coronavirus
(MERS-CoV) [19–20] and the most recent being
SARS-CoV-2 causing COVID-19 in humans ([4, 12,
13, 20, 21]; Figure 2). The first case of SARS, present-
ing with atypical pneumonia, was documented in late
2002 in the Guangdong province of China [5, 14, 17,
18, 20]. The SARS epidemic caused 8,096 reported
cases with 774 deaths, in many countries of the
world [17–20]. MERS, first reported in Saudi Arabia
in the year 2012, caused only 2521 cases with 866
deaths. It proved more fatal than SARS-CoV-1 with
CFR 34% versus 11% for MERS [17–20, 22]. SARS-
CoV-1 evolved to jump the species barrier through
intermediate hosts “masked palm civets and raccoon
dogs” causing epidemic, while MERS-CoV jumped
through the intermediate host “dromedary camels”
to infect humans ([5, 14, 19, 20]; Figure 2). MERS
cases still occur periodically, likely resulting from
occasional spill-over from the intermediate host “dro-
medary camels” [5, 12–14, 18–20, 22].
SARS-CoV-2 is more contagious compared to
SARS-CoV-1 and MERS-CoV [5, 12, 20]. The basic
reproductive number (R0 value) of SARS-CoV-2 is
still controversial. The early estimates of R0 value for
SARs-CoV-2 ranged from 2.2–3.1 [23, 24]. The recent
estimates, however, indicate that the number of SARS-
CoV-2 infected individuals doubles every 2.4 days
during the early epidemic, and R0 is likely to range
from 4.7–6.6 [25–28]. In a recent report, R0 of 3.54
was estimated for SARS-CoV-2 in the early outbreak
in Wuhan, China [29] that is much higher than
those reported for SARS-CoV-1 and MERS; the
authors identified two key features of the outbreak
in Wuhan: high covertness and high transmissibility
of the SARS-CoV-2 infections [29]. Effective multi-
pronged interventions and mitigation measures have
considerable positive effects on controlling the out-
break i.e. decreasing the R0 value [29]. The higher
transmission rates of the virus imply that short-term
control measures (lockdowns, self-isolation and
Figure 2. Human coronaviruses. The figure shows seven human coronaviruses, their origins, natural reservoirs, intermediate hosts,
tissue/organ tropism and reverse zoonosis along with primary and potential secondary and tertiary zoonotic events. An interroga-
tive sign (?) indicates unknown or unidentified.
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quarantines) have to be replaced by long-term
measures through effective prophylactic vaccine [25,
27–29].
Although bats are considered a natural reservoir of
more than 5,000 diverse CoVs, only about 500 of them
have been identified [5, 12, 14, 21, 30]. Based on com-
parative phylogenetic analyses, bats are considered the
most likely natural reservoirs of SARS-CoV-1 and
MERS-CoV. Bats have co-evolved with viruses for
millions of years. The co-evolution has led bats to con-
stitutively express higher levels of type I and type III
interferons in their body cells. The interferons are
known for inducing a large variety of antiviral genes,
called Interferon-stimulated genes (ISG), which limit
viral replication [5, 13, 16]. On the other hand, bats
induce a very subdued tissue destructive and patho-
genic inflammatory response to viruses. Viral infec-
tions in bats do not produce excessive amounts of
cytokines and other pro-inflammatory mediators
that are responsible for causing disease [5, 13, 16].
Furthermore, bats also exert attenuated responses to
several pathogen-associated (e.g. viral RNA) and
danger-associated molecular patterns (e.g. cytosolic
DNA). It is noteworthy that a subset of ISG, such as
RNA-dependent adenosine deaminases (ADARs)
and apolipoprotein B mRNA editing enzyme catalytic
polypeptide-like (APOBEC) family genes, promote
mutations in the viral RNA leading to the emergence
of novel viral strains, and at the same time attenuating
host’s innate immune responses to viral RNA [31, 32].
Thus, the persistence of viral infections, increased
RNA editing, and longer life span of bats increase
the probability of viral mutations and recombination
events, which potentially contribute to the emergence
of infectious and pathogenic CoV strains for other
species. It is not surprising that bats act as reservoirs
for CoVs as well as for many other highly pathogenic
viruses, including rabies and hemorrhagic fever
viruses [5, 11–14].
Unlike in bats, CoV infections in humans show a
wide spectrum of disease severities. They may be
asymptomatic, mild or severe, and may result in
death [11, 16]. The severity of the disease depends
upon the degree to which the infected host can
mount an antiviral response without eliciting a self-
destructive inflammatory response [11, 12]. The fac-
tors that determine nature of the host response
could be both of viral and host origins [11, 16, 33].
A viral strain that has been circulating in the host
and hence adapted to it, will be less pathogenic.
Host’s genetic propensity to exert excessive inflamma-
tory response and the presence of pre-existing chronic
inflammatory conditions (e.g. obesity, old age, cardio-
vascular disease, etc.) are known to aggravate the dis-
ease severity in COVID-19 patients [11, 12, 16].
Recent studies have shown that a prior exposure of
humans to other Coronaviruses (SARS and/or
“common cold”-causing ones), induces cross-reactive
antibodies and memory T cells that protect them
when they contract SARS-CoV-2 infection [34].
About 20–50% of humans were shown to have such
protection; they are likely to have no or mild clinical
symptoms upon infection with SARS-CoV-2.
Similar to other RNA viruses, CoVs are prone to
random mutations as they possess a relatively large
RNA genome with a limited proof-reading activity.
The mutation rate in SARS-CoV-2 (<25 mutations/
year) is, however, less than that of influenza A virus
(≥50 mutations/year; [35, 36]). Recent studies suggest
that SARS-CoV-2 continues to evolve as new
mutation hotspots/ mutated strains of this virus are
emerging in different parts of the world [35, 37].
The ultimate aim of viruses such as SARS-CoV-2 is
to attain a point of equilibrium with their host and
become endemic without causing high mortality in a
susceptible host population. European, North Ameri-
can and Asian viral strains may possibly coexist, each
characterized by a different mutation patterns in var-
ious viral genes, including RNA-dependent – RNA
polymerase (RdRp) and Spike [35, 37]. The character-
ization of viral mutations is important not only for
understanding viral drug resistance, immune evasion
and pathogenesis-related mechanisms, but also for
the development of vaccines, and designing antiviral
drugs and diagnostic assays [35, 37].
SARS-CoV-2 interspecies infections
Since the initial reports of mysterious pneumonia
(COVID-19 pneumonitis) from Wuhan in China,
there has been significant debate on why SARS-
CoV-2 infects humans, and several hypotheses have
been proposed. Through their Spike (S) protein, all
CoVs bind their receptors on host cells and initiate
the infection. The cleavage of S protein two segments
(S1 and S2) by a host protease is essential for the infec-
tion. S1 carries the receptor-binding domain (RBD),
which determines its specificity for the viral receptor
on host cells. Mutations in S protein of SARS-CoV-
2, due to natural selection, might have resulted in its
higher affinity for human angiotensin converting
enzyme-2 (ACE2) receptors [21]. The receptors are
expressed in nasal mucosa, bronchus, lung, heart, eso-
phagus, kidney, stomach, urinary bladder, testes and
ileum [38], making these human organs highly vulner-
able to infection with SARS-CoV-2.
It has been well known that the amino acid
sequences of the cleavage peptide at the S1 and S2
junction determine the peptide’s susceptibility to
different host proteases, and contribute to viral tissue
tropism, host range and pathogenesis. As mentioned
above, the surface unit S1 binds to a cellular receptor,
while the transmembrane unit S2 facilitates fusion of
the viral membrane with cellular membrane. SARS-
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CoV-2 has acquired a polybasic cleavage site contain-
ing arginine residues at the S1/S2 junction. The acqui-
sition is an important evolutionary step necessary for
the viral cross over to humans [21, 39, 40]. The poly-
basic site is important for several reasons. First, the site
enables cleavage of S protein into S1 and S2 segments
by furin, a ubiquitous protease, facilitating rapid viral
dissemination from lungs to other tissues. Second,
residues in the cleavage site influence 3D structure
of S-protein, its furin binding affinity and alter viral
virulence. Third, proteolytic cleavage of SARS-CoV-
2 S-protein by furin is a prerequisite for subsequent
activation (cleavage) of S2 by another host cell pro-
tease, the Transmembrane Serine Protease 2
(TMPRSS2), an essential step for viral entry into a
host cell. Last but not the least, the SARS-CoV-2 S1/
S2 cleavage site is identical to the furin-cleavage site
present in the human epithelial sodium channel α-
subunit (ENaC-α) [41]. In distal lung airways, ENaC
is known to play a key role in controlling fluid reab-
sorption at the air–liquid interface. The proteolytic
activation of ENaC-ɑ by furin is required for the func-
tional activation of this channel. It has been postulated
that the viral S protein competes with ENaC-α for
furin engagement leading to poor fluid reabsorption
in the lungs of COVID-19 patients [41].
The importance of a polybasic furin cleavage site
for tissue tropism and viral pathogenicity has been
well documented in avian influenza A viruses. Analo-
gous to the SARS CoV-2 S protein, the hemagglutinin
(HA) of the Influenza viruses needs cleavage into HA1
and HA2 segments for their entry into host cells [42].
The viruses have been classified into low – or high-
pathogenic avian influenza viruses (LPAIVs or
HPAIVs, respectively) [42]. The LPAIVs cause asymp-
tomatic or mild infections whereas HPAIVs cause
severe systemic infections in poultry with high mor-
tality. Remarkably, the LPAIVs possess a monobasic
(usually a single arginine) cleavage site at the HA1/
HA2 junction. The site is cleaved by trypsin and tryp-
sin-like proteases, whose expression is restricted to
avian respiratory and intestinal tract tissues [42]. On
the other hand, the HA of HPAIVs contains a polyba-
sic motif, which is cleaved by ubiquitously expressed
proprotein convertases such as furin leading to severe
systemic infections with high mortality. Interestingly,
HPAIV strains emerge from LPAIV by insertion of
multiple basic amino acids at the cleavage site loop.
Thus, the acquisition of a polybasic cleavage site is
an essential feature for the evolution of HPAIV from
LPAIV.
Given the fact that SARS-CoV-2 is the only virus
among SARS-related viruses whose S protein contains
a peculiar furin cleavable polybasic cleavage site, the
feature most likely contributes to the viral transmissi-
bility, zoonotic potential, wide-spread tissue distri-
bution and a wide spectrum of clinical symptoms. A
recent study suggests that a D614G mutation in the
S-protein, which renders S protein more susceptible
to cleavage by furin and TMPRSS2, is linked to a
higher transmission rate of SARS CoV-2 [43, 44]. In
addition to SARS CoV-2, many other human viruses
of medical importance such as HIV-1, measles virus,
respiratory syncytial virus, and Ebola virus require
furin for cleavage and activation of their receptor-
binding surface glycoproteins [42]. Unfortunately,
because of its essential role in a wide array of cellular
functions, furin cannot be targeted for devising anti-
viral strategies.
SARS-CoV-2 shares 96.2% identity at the nucleo-
tide level with RaTG13, a CoV detected in horseshoe
bat species, Rhinolophus sinicus; this virus, however,
has not been detected in humans [21]. Although
horseshoe bat has been proposed to be the natural
host of SARS-CoV-2, no direct evidence on the exist-
ence of SARS-CoV-2 infection in the bats is documen-
ted to date. Despite the homology, the RaTG13 RBD is
very divergent from that of the SARS CoV-2. Possibly
due to selective pressure, the SARS-CoV-2 RBD, after
evolving in horseshoe bats, has evolved further in a
non-bat intermediate animal species before its zoono-
tic transfer to humans. In this regard, it is interesting
to note that the SARS CoV-2 RBD is very similar to
the one found in the SARS-related β-CoVs of Malayan
pangolin [45–48], an endangered mammalian species.
The viral sequences were found in archived samples of
pangolins, who, similar to COVID-19 patients, had
exhibited clinical symptoms such as cough and short-
ness of breath [46–48]. Moreover, there was evidence
of vertical transmission of the SARS-related β-CoVs in
pangolins, suggesting virus circulation in this natural
population [48]. However, testing of throat and rectal
swabs from 334 pangolins sampled from the market’s
upstream supply chain, did not yield any positive PCR
results for this CoV’s nucleic acid sequences [46],
suggesting that positive samples from pangolins in
the market may have resulted from exposure to
infected humans, wildlife or other animals. Thus, the
existing evidence does not conclusively support the
hypothesis that RaTG13 or pangolin β-CoV is the
immediate parental virus of SARS-CoV-2. A recent
phylogenetic analysis indicates a strong purifying
selection around SARS-CoV-2 RBD and other genes
among bat, pangolin, and human CoVs through
recombination event(s) with CoVs from pangolins
giving SARS-CoV-2 surface protein the ability to
infect human cells [49]. It is likely that SARS-CoV-
2’s RBD became optimized through pre-adaptation
in pangolins for binding to human ACE2 receptors
with high affinity. Biophysical and structural evidence
suggests that the SARS-CoV-2‘s RBD is likely to bind
human ACE2 with 10–20-fold higher affinity than that
of SARS-CoV-1 [21, 45, 50–52]. To date, there is not
enough scientific evidence to accurately explain the
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original route of SARS-CoV-2 transmission to
humans, which may involve an un-identified inter-
mediate host. Further investigations are required to
establish an evolutionary pathway of SARS-CoV-2 in
bats, pangolins and/or other mammals. Since the cat
ACE2 gene is the closest to the human’s among
non-primate animals, and can potentially bind with
both SARS CoV-1 and SARS CoV-2 S proteins [53],
it is important to monitor the presence of SARS-
CoV-2 infection in cats because human patients with
COVID-19 may potentially transmit this virus to cats.
The current concept is that parental viruses of
HCoVs are archetypically non-pathogenic in their
natural reservoir host(s) but become pathogenic after
their transmission to a new host species. With further
evolution, the viruses adapt to the new host and
become more transmissible and less pathogenic [5,
43, 44]. It is therefore possible that a progenitor of
SARS-CoV-2 jumped into humans and adapted
from being more virulent to a more transmissible
viral strain responsible for the current pandemic [21,
43, 44]. It is important to note that SARS-CoV-2
shows pathogenicity less than that of the SARS-
CoV-1 andMERS-CoV but a transmissibility potential
similar to or greater than that of the – community-
acquired HCoVs (NL63, 229E, OC43, and HKU1)
[5]. It is highly probable that the virus in humans
will continue to evolve on this line and adapt further
to humans and become less pathogenic unless inter-
vened by therapeutics and/or prophylactic vaccines.
The dynamics of viral quasi-species resulting from
genetic variation, competition and selection might
have played a role in SARS-CoV2 adaptation to infect
human cells. The quasi-species phenomenon has
been reported for several RNA viruses including
SARS CoV-1 and MERS-CoV [54, 55]. A recent
genomic analysis of 103 viral isolates suggests that
SARS-CoV-2 has evolved into S and L types [56],
although the clinical significance of these two types
is uncertain. It is possible that one strain type is
more pathogenic than the other. Several genotypes,
antigenic types and pathotypes of SARS-CoV-2 are
possibly circulating among human populations.
Future studies involving a large number of viral iso-
lates might help to characterize genotypes and poten-
tial antigenic variants of this virus. The
characterization will have important implications
for the development of therapeutics, vaccines and
diagnostic approaches.
SARS-CoV-2: experimental infections
These infections are important to investigate patho-
genetic mechanisms of the virus, host immune
response and efficacy of different drugs and vaccines.
In this regard, structural modelling of the SARS-
CoV-2 S protein and ACE2 receptors indicates that
the virus could bind and perhaps infect bat, civet,
monkey and swine cells [57]. However, host range
projections based on modelling are sometimes not
correct and require in-vivo studies in animals to
determine the host range of the virus [30]. Based
on structural modelling of these proteins, Asian
and African primates are likely more susceptible to
SARS-CoV-2 compared to the South and Central
American primates [51]. On the bases of viral gen-
ome sequence analyses, and structural and biochemi-
cal studies, it seems more likely that the SARS-CoV-
2’s RBD binds with high affinity to ACE2 from
humans and ferrets [52, 57–59, 60–62]. In concor-
dance with these findings, Macaques (Macaca fasci-
cularis and Macaca mulatta), ferrets and Syrian
golden hamsters were not only found to be highly
susceptible to experimental infection with SARS-
CoV-2 but these animals could also transmit the
infection to their cage mates (Table 1; [51, 57–59]).
Macaques develop respiratory signs very similar to
those of COVID-19 patients [51] whereas in Syrian
golden hamsters and ferrets, SARS-CoV-2 infections
cause none or mild respiratory signs [57–59]. These
animal species appear to be suitable animal models
for investigations on COVID-19 [51, 58, 59].
Recently, North American deer mice (Peromyscus
maniculatus) was also shown to be susceptible to
experimental infection with SARS-CoV-2 [60].
ACE-2 receptors of these mice possess key amino
acid residues that allow cell binding to SARS-CoV-
2 S protein. However, the risk of reverse zoonosis
and/or potential role of this animal species as a reser-
voir for SARS-CoV-2 needs further investigation.
Initial findings suggest that chickens, ducks, turkeys
and pigs are refractory to infection by SARS-CoV-2
under experimental conditions [57].
Recently, it was shown that the bat intestinal orga-
noids (more specifically enteroids) were susceptible
to infection with SARS CoV-2 and showed cytopathic
effects [63]. This is not surprising considering 80.5%
amino acid sequence similarity between human and
horseshoe bat ACE-2 receptors. The establishment
and characterization of the bat enteroids that simu-
late the cellular composition of the bat intestinal epi-
thelium might allow rapid and robust isolation and
study of SARS-CoV-2 isolates or its progenitor(s)
with higher efficiency than Vero E6 cells; later
being the most commonly used cell line for SARS-
CoV-2 isolation and characterization [63]. In
addition, the authors also reported active SARS-
CoV-2 replication in human enteroids, suggesting
that human intestinal tract might be an additional
route for viral transmission [63]. Whether the intes-
tinal epithelial cells are primarily infected with SARS-
CoV-2 via the oral–fecal route or enteric infection
occurs post-respiratory infection needs to be
investigated.
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Table 1. Animal Species Susceptibility to SARS-CoV-2.
Species Susceptibility Infection type Clinical signs Transmission References





None or very mild (respiratory signs possible; comorbidities may increase the
susceptibility or severity of signs)
None reported; dogs may shed virus in nasal secretions [57, 64–70]
Domestic Cats High Natural/
Experimental
None or mild (mild respiratory signs such as sneezing, transparent ocular discharge,
and lethargy; presence of other respiratory pathogens or comorbidities may increase
the severity of the signs)
Cat to cat; cats shed virus in their nasal secretions and feces;
air-borne transmission reported among cage mates
[53, 57, 64–66,
68, 70–73]
Poultry (chickens and ducks) None Experimental None None [57, 80]
Pigs None Experimental None None [57, 80]
Ferrets High Experimental None or mild (sneezing, elevated temperature, reduced activity and occasional cough) Ferret to ferret; ferrets shed virus in nasal secretions, saliva,
urine and feces; air-borne transmission among cage mates
reported




High Experimental Moderate signs (irregular respiratory pattern, reduced appetite, hunched posture, pale
appearance, dehydration, elevated temperature and weight loss as well as
pulmonary infiltrates evident on lung radiograph)





High Experimental None or mild (rhinitis) Bat to bat; fruit bats shed virus via respiratory, oral and fecal
routes
[80]
Farmed Minks High Natural None or moderate to severe signs (gastrointestinal and respiratory signs, pneumonia
and increased mortality rate)
Human to mink, mink to mink, mink to cat possible, mink to
human possible; minks shed virus in respiratory and oral
secretions as well as in feces
[66, 74]
Golden Syrian Hamsters High Experimental Mild (progressive weight loss, lethargy, ruffled furs, rapid breathing and hunched back
posture)
















Reverse zoonosis (Zooanthroponosis) and
secondary zoonosis
Sporadic detection of natural SARS-CoV-2 infections
together with successful experimental infections of
certain animals raises concerns about reverse zoonosis
(also termed as zooanthroposis: transmission of the
infection from humans to animals) as well as about
secondary zoonotic events (transmission of the infec-
tion from animals back to humans). Several cases of
dogs, cats and zoo animals have tested positive for
SARS-CoV-2, mostly as a result of close contact with
infected humans (Table 2; [64–66]). However, the
occurrence of natural infections in these animal
species has not been ruled out. There is a limited infor-
mation available on clinical manifestations of SARS-
CoV-2 in animals. The existing evidence suggests
that the clinical manifestations may range from covert
infections to symptomatic disease with signs that may
include coughing, sneezing, respiratory distress, nasal
discharge, ocular discharge, vomiting or diarrhea,
fever, and lethargy, etc. (Table 1). The detection of
asymptomatically prevalent infections in companion
animals, and estimation of their proportionate contri-
bution in the spread of SARS-CoV-2 to humans and
other animal species, if any, requires further
investigations.
A report from Hong Kong in February 2020
suggested the possible presence of SARS-CoV-2 infec-
tion without any signs of illness in two dogs (Table 2;
[67]); the owner of these dogs was previously diag-
nosed with COVID-19. The first case was a 17-year
old Pomeranian breed dog, who tested positive for
SARS-CoV-2 RNA by RT–PCR on multiple nasal
and oral swabs. However, the virus could not be iso-
lated from the dog’s samples; mere presence of viral
RNA does not decisively confirm active infection; ser-
ological testing, virus isolation and/or serial quantifi-
cation of viral nucleic acids are required to confirm
the infection. Although the dog tested negative on
subsequent RT–PCR testing, seroconversion was
noted in the initial sample, but additional testing
was not possible due to unavailability of convalescent
serum; the geriatric dog passed away three days later
presumably due to some other underlying health pro-
blems. It was therefore concluded that the dog either
had a low-level of infection or was contaminated
with SARS-CoV-2 by close contact with and/or
exposure to an infected person. The second case was
a two-year old German Shepherd dog, who tested
positive by RT–PCR in quarantine after its owner
was confirmed to have COVID-19 [67, 68]. The first
dog in the US reported to test positive for SARS-
CoV-2 was a six-year old male German Shepherd,
whose owner had confirmed COVID-19 (Table 2;
[69]). The dog tested positive in mid-April 2020 and
was euthanized on 11 July 2020. Although the dog
tested negative on RT–PCR for SARS-CoV-2 five
days later, he did develop anti-SARS-CoV-2 anti-
bodies indicating he had active infection. This dog
showed signs of muco-purulent nasal discharge with
laboured breathing and lethargy [69]. The additional
signs noted were blood in the urine, clotted blood in
the vomit, troubled walking and weight loss. This
dog was also diagnosed with lymphoma and heart
murmurs [69]. This case raised two important ques-
tions. First, what signs (if any) in this dog were due
to SARS-CoV-2 infection, and second, whether
comorbidities such as heart problems, or cancers,
play any role in increasing the susceptibility of compa-
nion animals to SARS-CoV-2 infection. Research has
shown that dogs exposed to SARS-CoV-2 could pro-
duce anti-SARS-CoV-2 antibodies without exhibiting
symptoms of COVID-19 [57, 68, 70].
In March 2020, the SARS-CoV-2 RNA was detected
in the feces and vomit contents of a cat by RT–PCR in
Belgium (Table 2; [70]). The cat belonged to an owner
who tested positive for SARS-CoV-2-. The cat exhib-
ited transient respiratory and gastrointestinal disease
one week after the owner became symptomatic for
COVID-19 [70]. Since no information on virus iso-
lation, seroconversion and blood results was available
at the time of this report, it was difficult to establish an
association between the cat’s clinical signs and active
SARS-CoV-2 infection. On 1 April 2020, a pet cat
tested positive for SARS-CoV-2 without showing any
clinical signs of illness in Hong Kong after her
owner was confirmed to have COVID-19 [70]. On
April 05, 2020, a four-year old Malayan tigress at the
Bronx Zoo in New York developed dry cough and
tested positive for SARS-CoV-2 (Tables 1 and 2;
[70]). Five other tigers and lions showed mild signs
of respiratory illness and later recovered completely
([65, 66, 70]; Figure 2; Table 2). A zoo employee, an
asymptomatic carrier of SARS-CoV-2, was deemed
responsible for transmitting the virus to these zoo ani-
mals. On 22 April 2020, two domestic cats tested posi-
tive for SARS-CoV-2 in the USA, one cat contracted
the infection from the virus-positive owner; the
other cat presumably got infected from a covertly
infected human [71]. As of 14 August 2020, 14 cases
of dogs and 13 cases of domestic cats in the USA
have tested positive for SARS-CoV-2 infection using
RT–PCR or virus neutralization antibody tests. All
these companion animals had exposure to either a
covertly infected or confirmed human(s) with
COVID-19 [65]. It has been shown that under exper-
imental conditions, domestic cats are susceptible to
infection with SARS-CoV-2 and can transmit the
virus to other cats via droplet or short-distance aerosol
([57, 70]; Table 1); the susceptibility of cats to SARS-
CoV-2 is explained by the fact that feline ACE-2
receptor differs only by three amino acids from that
of humans [53]. According to a report, SARS-CoV-2
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had infected cat population in Wuhan during the
COVID-19 outbreak; 14.4% cat sera collected before
and after the COVID-19 outbreak were positive for
antibodies specific to the RBD of SARS-CoV-2 by
indirect enzyme linked immunosorbent assay [72].
Among the 15 positive cat sera, 11 serum samples
had various titers of SARS-CoV-2 neutralizing anti-
bodies; the authors did not detect any serological
cross-reactivity between the SARS-CoV-2 and FIPV.
Recently, a large-scale study involving 500 companion
animals (dogs and cats) living in COVID-19-
positive and – negative households in Northern Italy
reported measurable SARS-CoV-2 neutralizing anti-
body titers in 3.4% dogs and 3.9% cats [73]. These
reports support the notion of human-to-animal
transmission (reverse zoonosis or zooanthroponosis)
of SARS-CoV-2.
In a recent report, minks showing signs of pneumo-
nia and mortality were confirmed to be infected with
SARS-CoV-2 at various farms in the Netherlands
([74]; Tables 1 and 2; Figure 2). It is believed that sev-
eral farm workers, who developed symptoms consist-
ent with COVID-19, transmitted the virus to the
minks. It is also likely that infected minks might
have transmitted the virus to some of the farm
workers. The transmission was evident from similarity
of viral sequences detected in infected individual to
those found in minks. Additionally, seven of 24 cats
at the mink farms also tested positive serologically
for SARS-CoV-2-specific antibodies [66, 74], and at
Table 2. Reverse zoonosis cases of SARS-CoV-2 reported in animals.
Case # MM/DD/YYYY Possible source of infectiond Animal Region/Country References
1 02/27/2020 Pet Owner Dog ab Hong Kong [66–68, 70]
2 03/18/2020 Pet Owner Dogabc Hong Kong [66–68, 70]
3 03/18/2020 Pet Owner Cata Belgium [66, 68, 70]
4 03/27/2020 Zoo Employee Tigera NY, USA [64–66, 70]
5 03/27/2020 Zoo Employee Liona NY, USA [64–66, 70]
6 03/30/2020 Pet Owner Catab Hong Kong [66, 70]
7 04/01/2020 Pet Owner Catab NY, USA [65, 66]
8 04/02/2020 Pet Owner Catb China [66]
9 04/04/2020 Zoo Employee Tigera NY, USA [64–66, 70]
10 04/06/2020 Pet Owner Catab NY, USA [65, 66]
11 04/15/2020 Zoo Employee Liona NY, USA [66, 70]
12 04/22/2020 Pet Owner Cata NY, USA [65, 66]
13 04/22/2020 Pet Owner Cata NY, USA [65, 66]
14 04/26/2020 Farm Worker Minkabc The Netherlands [66, 74]
15 04/28/2020 Pet Owner Doga NC, USA [65, 66]
16 05/01/2020 Pet Owner Cata France [66]
17 05/08/2020 Pet Owner Cata Spain [66]
18 05/08/2020 Farm Worker Minkabc The Netherlands [66, 74]
19 05/12/2020 Pet Owner Cata France [66]
20 05/13/2020 Pet Owner Cata Germany [66]
21 05/15/2020 Farm Workers/Infected Minks Catab The Netherlands [66]
22 05/15/2020 Human Dogb The Netherlands [66]
23 05/18/2020 Pet Owner Cata Russia [66]
24 05/21/2020 Human Cata Spain [66, 73]
25 05/25/2020 Human Catb The Netherlands [66]
26 05/27/2020 Pet Owner Dog NC, USA [65, 66]
27 06/01/2020 Pet Owner Dogab NY, USA [65, 66, 69]
28 06/01/2020 Pet Owner Cata MN, USA [65, 66]
29 06/02/2020 Farm Worker Minkabc The Netherlands [66]
30 06/02/2020 Pet Owner Doga NY, USA [65, 66]
31 06/03/2020 Pet Owner Catac MN, USA [65, 66]
32 06/04/2020 Pet Owner Cata IL, USA [65, 66]
33 06/24/2020 Pet Owner Dogb NY, USA [65, 66]
34 06/24/2020 Pet Owner Dogb NY, USA [65, 66]
35 07/01/2020 Pet Owner Doga GA, USA [65, 66]
36 07/08/2020 Pet Owner Doga TX, USA [65, 66]
37 07/08/2020 Pet Owner Cata GA, USA [65, 66]
38 07/09/2020 Pet Owner Doga SC, USA [65, 66]
39 07/15/2020 Pet Owner Doga AZ, USA [65, 66]
40 07/21/2020 Pet Owner Cata TX, USA [65, 66]
41 07/22/2020 Pet Owner Catb UT, USA [65, 66]
42 07/22/2020 Pet Owner Catb UT, USA [65, 66]
43 07/22/2020 Pet Owner Dogb UT, USA [65, 66]
44 07/22/2020 Pet Owner Dogb WC, USA [65, 66]
45 07/22/2020 Pet Owner Dogb WC, USA [65, 66]
46 07/22/2020 Pet Owner Dogb NC, USA [65, 66]
47 08/03/2020 Pet Owner Doga LA, USA [65, 66]
48 08/11/2020 Pet Owner Doga NC, USA [65, 66]
49 08/12/2020 Pet Owner Catb NY, USA [65]
50 08/17/2020 Farm Worker Minka Utah, USA [65]
51 08/17/2020 Farm Worker Minka Utah, USA [65]
aPositive by RT-PCR.
bPositive by virus neutralizing antibodies.
cPositive on virus isolation in cell culture.
dSARS-CoV-2 positive (symptomatic or asymptomatic) pet owners, animal caretakers or farm workers most likely transmitted the virus to animals.
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least one seropositive cat tested positive for the SARS-
CoV-2 RNA. Although, neither the source of the virus
(infected minks or infected farm workers) in cats nor
transmission of the virus from cat(s) to other animals
or humans could be confirmed, the possibility of inter-
species transmission of the virus, i.e. primary and sec-
ondary zoonotic events cannot be ruled out.
Given the evidence in this review, it is apparent that
certain CoVs have crossed, and will continue to cross
host species. A strong possibility exists that SARS-
CoV-2 has been transmitted from humans to farmed
minks and companion and zoo animals. The conse-
quences of such zooanthroponosis are unknown at
the moment. The interspecies transmission among
animals could make the pandemic control more
difficult. It should, however, be noted that as of
today, there is no conclusive evidence that cats,
dogs, or zoo animals can transmit SARS-CoV-2 to
humans. Based on the current information, the overall
risk of SARS-CoV-2 transmission from companion
and zoo animals to other animals or humans as well
from humans to animals is low. However, uncertainty
remains on how this virus will behave in various ani-
mal species. Thus, urgent and planned investigations
and continuous monitoring as well as targeted proac-
tive surveillance of specific animals and their care-
takers, with known or suspected exposures to
humans with COVID-19, are warranted at local and
national levels.
Currently, there is not enough SARS-CoV-2
specific testing being done for companion and zoo
animals. However, the situation may change in future.
It is noteworthy that the USA IDEXX Laboratories
have recently launched a test under the commercial
name “SARS-CoV-2 (COVID-19) Real PCR Test” to
test samples from companion animals [75]. Several
other private and government veterinary laboratories
are also in the process of developing and using serolo-
gical assays and nuclic acid-based tests for SARS-CoV-
2 detection in pet and zoo animals.
The One-Health initiative and potential for
secondary zoonotic events
The One-Health concept is based upon the premise
that human health is intricately linked to, and depen-
dent upon, the health of all the living creatures of this
planet as well as of their habitats. Together they form
an ecosystem, whose health ultimately affects human
health (Figure 3). Therefore, it dictates that a
collaborative, multisectoral, and transdisciplinary
approach should be adopted at a global level for
achieving the best possible health outcomes for people,
animals, plants, and their shared environment. Over
the last two decades, an alarming upsurge in newly
emerging and certain re-emerging pathogens was
observed [76]. During this period, three pathogenic
CoVs have struck humans, and the probability of
another one is quite certain. This scenario leaves no
option other than adopting One Health-One World
approach. It is worth noting that about 60% of
known infectious diseases in humans are zoonotic
and about 70% of emerging infectious diseases in
humans are also of zoonotic origin [77]. Several fac-
tors may account for the increases in infectious dis-
eases of zoonotic origin. They include climate
change, urbanization, rapid population growth,
expansion of new geographic areas, lifestyle changes,
eating habits, intensive farming systems, deforesta-
tion, land use changes, increased human national
and international travel, and increased movements
of animals and animal products across the globe for
trade. These changes affect human and animal health,
and the ecosystems, resulting in rapid spread of infec-
tious diseases. They increase the probability of SARS-
CoV-2 jumping not only from animals into humans
through primary and secondary zoonotic events, but
also from humans to animals through reverse spread.
They also enhance the potential for emergence of new
genotypes, pathotypes and/or antigenic types of SARS-
CoV-2. Because of the ability of the virus to infect
multiple host species, it could be quickly shipped via
asymptomatic human carriers, infected animals and/
or food products from one location to the other.
Figure 3. SARS-CoV-2 and the One-World – One-Health con-
cept. It emphasizes that human health is dependent and intri-
cately connected with that of animals (domestic and wild),
birds and plants. A disturbance in the ecosystem results in
human diseases (zoonotic or reverse-zoonotic). The letter X
denotes a zoonotic event; the color red, white and yellow
depict potential primary, secondary and tertiary zoonotic
events, respectively.
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The World Organization for Animal Health (Office
International des Epizooties; OIE), the WHO and
Food and Agriculture Organization (FAO) of the Uni-
ted Nations, the United States Department of Agricul-
ture (USDA) and Center for Disease Control and
Prevention (CDC), and many other global and local
organizations are advocating and promoting the
One-Health for One World approach. The occurrence
of global epidemics such as HPAI, Ebola, SARS,
MERS, and recently COVID-19 [33, 76–79] has pro-
vided stimulus to further strengthen the One-Health
programme, especially in developing nations, and
leveraging the expertise of veterinarians to support
global public health community [79].
The One-Health approach recommends that
veterinarians, medical doctors and human and ani-
mal health specialists be involved in inter-disciplin-
ary collaboration to fight against not only COVID-
19 but also against other newly emerging patho-
gens, which constantly threaten human and animal
health as well as food safety and security. Adopting
a One-Health strategy will not only help in devel-
oping and implementing effective strategic planning,
policies, and procedures leading to timely disease
agent detection and prevention but also in a coor-
dinating emergency response and a solid contin-
gency plan for future pathogens. The increased
awareness on zoonotic and reverse zoonotic poten-
tial of SARS-CoV-2, and their mitigation measures
should be communicated to the general public.
The COVID-19 pandemic has also highlighted the
importance of local provisions of essentials (e.g.
food, medical equipment, and lifesaving drugs),
and reduced dependency on global infrastructure.
Veterinarians, microbiologists, epidemiologists and
animal biologists might help to predict the emer-
gence and potential source(s) of future outbreaks
of infectious diseases. Surveillance of wild, food
and domestic animal population is the key to pre-
venting SARS-CoV-2 from establishing itself in
another animal species, especially in companion
and food animals. Future investigations on reverse
zoonotic potential of SARS-CoV-2 should focus
on disease transmission routes, prevalence, patho-
genesis, and prevention mechanisms. It is unlikely
that SARS-CoV-2 will be the last coronavirus to
jump species barrier infecting human(s) and other
animal species.
The lessons learned from COVID-19 pandemic
could be used to create awareness for strengthening
the veterinary and medical profession on modern
grounds. This will aid veterinary professionals to effec-
tively contribute to not only animal but also to public
health at local, national, and global levels. The collec-
tive knowledge found, resources developed, and
capacity built could be used for a more collaborated,
rapid and effective emergency response that keeps in
check the future spread of emerging epidemics at a
both national and international level.
Conclusions
SARS-CoV-2 is a zoonotic disease that has crossed
species barrier from its reservoir bat host, and
infected humans via an unknown intermediate ani-
mal species. The disease, declared as a pandemic,
has caused a great loss to human life and economy,
and has disrupted our routine social life. The virus
has clearly shown the potential of reverse zoonosis.
During the last six months there have been consist-
ent reports of the viral infections in companion,
zoo and certain farm animals. The specter of pri-
mary and secondary zoonotic events, although not
yet confirmed, has also been raised. We should con-
tinue to adhere to traditional measures of control-
ling the pandemic (lockdowns, physical distancing,
testing and isolating the infected individuals,
increased personal hygiene and protection of vul-
nerable) until effective therapies and vaccines are
developed. The recommendations of the One-
Health One-World should be implemented to pre-
vent the emergence of future epidemic(s) and pan-
demic(s).
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